AIS 2025 – France: Highlights and Event Recap

The 13th Antibody Industrial Symposium 2025 was held in Tours, France, from June 25-26. This event covers the latest advances and associated challenges in the field of therapeutic antibodies and their derivatives, recombinant proteins and other biomedicines, from R&D and into clinical phases. Popular topics include:

• Discovery and optimization of multispecifics and immunocytokines 

• AI-based computational approaches 

• Biomarker assay development for ADC selection 

• Fc domains of mAbs 

• ADCs, BsAbs, Fc-fusion proteins 

→ Biointron’s Highlighted Points:

1. Multispecific Antibodies & Immune Redirection

• Multispecific antibodies are rapidly evolving, enabling broader target engagement and novel immunotherapeutic strategies. 

• CD3, CD28/CD47, and HER3 bispecifics, as well as MAIT and NK-cell engagers, offer synergistic mechanisms to enhance anti-tumor efficacy. 

• T-cell engagers are promising therapies across both solid and hematologic cancers. 

2. Antibody-Drug Conjugates (ADCs)

• Next-gen ADCs, such as anti-Napi2b and CD71-targeting molecules, show durable efficacy with improved tolerability and druggability. 

• Site-specific DAR1 conjugation, novel payloads like vincristine, and FDC formats enhance targeting and safety. 

• Multi-payload and fragment-based ADCs introduce modularity, deeper tissue penetration, and broader therapeutic scope. 

3. Novel Targets & Single-Domain Antibodies

• Single-domain antibodies show promise in oncology, fertility, reproductive health, and neurodegenerative conditions. 

• New targets such as FSH, gonadotropin receptors, and TRPV6 expand therapeutic reach. 

• SPR-based and imaging-enabled sdAbs provide precision tools for diagnostics and treatment. 

4. Fc Domain Engineering

• Fc modulation impacts potency, pharmacokinetics, and immune activity in mAbs, ADCs, and fusion proteins. 

• Alternative Fc strategies challenge traditional effector-silencing methods, while LC/MS studies inform function–structure relationships. 

5. AI in Antibody Discovery & Engineering

• AI/ML platforms accelerate immuno-oncology discovery, antibody funnel design, and engineering efficiency. 

• Explainable AI and real-world data are being used to optimize strategies for diseases like IBD. 

6. Emerging Platforms & Early Innovation

• Innovations like pH-modulated checkpoint antibodies, microfluidics, MAPPs assays, and algae-based production improve early-stage development. 

• Optimized screening and sustainable manufacturing support robust mAb and BsAb pipelines. 

• Subcutaneous, inhaled, and CNS-targeted biologics improve patient access and administration routes. 

• VHHs, nanocarriers, and IgG nebulization enhance delivery, especially in neurological and respiratory applications. 

Thank you to everyone who visited our booth at AIS to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.